2012 NIOSH List of Antineoplastic and Other Hazardous Drugs

Total Page:16

File Type:pdf, Size:1020Kb

2012 NIOSH List of Antineoplastic and Other Hazardous Drugs NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012 DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention National Institute for Occupational Safety and Health NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012 DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention National Institute for Occupational Safety and Health This document is in the public domain and may be freely copied or reprinted. Disclaimer Mention of any company or product does not constitute endorsement by the National Institute for Occupational Safety and Health (NIOSH). In addition, citations to Web sites external to NIOSH do not constitute NIOSH endorsement of the sponsoring organizations or their programs or products. Furthermore, NIOSH is not responsible for the content of these Web sites. Ordering Information To receive documents or other information about occupational safety and health topics, contact NIOSH at Telephone: 1–800–CDC–INFO (1–800–232–4636) TTY:1–888–232–6348 E-mail: [email protected] or visit the NIOSH Web site at www.cdc.gov/niosh For a monthly update on news at NIOSH, subscribe to NIOSH eNews by visiting www.cdc.gov/niosh/eNews. DHHS (NIOSH) Publication Number 2012−150 (Supersedes 2010–167) June 2012 Preamble: The National Institute for Occupational Safety and Health (NIOSH) Alert: Preventing Occupational Exposures to Antineoplastic and Other Hazardous Drugs in Health Care Settings was published in September 2004 (http://www.cdc.gov/niosh/docs/2004-165/). In Appendix A of the Alert, NIOSH identified a sample list of major hazardous drugs. The list was compiled from infor- mation provided by four institutions that have generated lists of hazardous drugs for their respec- tive facilities and by the Pharmaceutical Research and Manufacturers of America (PhRMA) from the American Hospital Formulary Service Drug Information (AHFS DI) monographs [ASHP/ AHFS DI 2003]. The 2004 list was updated in 2010; this update adds 26 drugs to the 2010 list. These additions are new drugs or existing drugs that had new warnings from 2007 to 2009. The review process for the addition of the new listings is described in the Federal Register: http://www.cdc.gov/ niosh/docket/archive/pdfs/NIOSH-190/0190-080211-frn.pdf Appendix A · Drugs Considered Hazardous General Approach to Handling toxic to the patient, some may not pose a risk to health care workers. Hazardous Drugs NIOSH and other organizations are still gath- In the Alert, NIOSH presents a standard pre- ering data on the potential toxicity and health cautions or universal precautions approach effects related to highly potent drugs and bio- to handling hazardous drugs safely: that is, engineered drugs. Therefore, when working NIOSH recommends that all hazardous drugs with any hazardous drug, health care workers be handled as outlined in the Alert. Therefore, should follow a standard precautions approach no attempt has been made to perform drug along with any recommendations included in risk assessments or propose exposure limits. the manufacturer’s MSDSs. The area of new drug development is rapidly evolving as unique approaches are being taken to treat cancer and other serious diseases. ASHP Definition of Hazardous Drugs Defining Hazardous Drugs ASHP defines hazardous drugs in their 1990 revision of Technical Assistance Bulletin on Hazardous drugs include those used for can- Handling Hazardous Drugs [ASHP 1990]. The cer chemotherapy, antiviral drugs, hormones, bulletin gives criteria for identifying poten- some bioengineered drugs, and other miscella- tially hazardous drugs that should be handled neous drugs. The definition of hazardous drugs in accordance with an established safety pro- used in the Alert is based on an ASHP defi- gram [McDiarmid et al. 1991; Arrington and nition that was originally developed in 1990 McDiarmid 1993]. The criteria are prioritized [ASHP 1990]. Thus the definition may not ac- to reflect the hierarchy of potential toxicity de- curately reflect the toxicity criteria associated scribed below. Since the hazardous drugs cov- with the newer generation of pharmaceuticals ered by the Alert were designed as therapeu- entering the health care setting. For example, tic agents for humans, human toxicity profiles bioengineered drugs target specific sites in the should be considered superior to any data from body; and although they may or may not be animal models or in vitro systems. Additional 1 guidance for defining hazardous drugs is avail- Organ toxicity at low doses† able in the following citations: carcinogenic- Genotoxicity‡ ity [61 Fed. Reg. 17960–18011 (1996b); IARC 2010], teratogenicity [56 Fed. Reg. 63798–63826 Structure and toxicity profiles of new drugs (1991)], developmental toxicity [56 Fed. Reg. that mimic existing drugs determined haz- 63798–63826 (1991)], and reproductive toxic- ardous by the above criteria ity [61 Fed. Reg. 56274–56322 (1996a)]. Physi- cal characteristics of the agents (such as liquid versus solid, or water versus lipid solubility) Determining Whether a Drug is also need to be considered in determining the Hazardous potential for occupational exposure. Many hazardous drugs used to treat cancer bind to or damage DNA (for example, alkylat- NIOSH Revision of ASHP Definition ing agents). Other antineoplastic drugs, some antivirals, antibiotics, and bioengineered drugs The 1990 ASHP definition of hazardous drugs* interfere with cell growth or proliferation, or was revised by the NIOSH Working Group on with DNA synthesis. In some cases, the non- Hazardous Drugs for the Alert. Drugs consid- selective actions of these drugs disrupt the ered hazardous include those that exhibit one growth and function of both healthy and dis- or more of the following six characteristics in eased cells, resulting in toxic side effects for humans or animals: treated patients. These nonselective actions can also cause adverse effects in health care Carcinogenicity workers who are inadvertently exposed to haz- Teratogenicity or other developmental ardous drugs. toxicity† Early concerns about occupational exposure to Reproductive toxicity† antineoplastic drugs first appeared in the 1970s. Although the antineoplastic drugs remain the *ASHP [1990] definition of hazardous drugs principal focus of the Alert, other drugs may 1. Genotoxicity (i.e., mutagenicity and clastogenicity also be considered hazardous because they are in short-term test systems) potent (small quantities produce a physiologi- 2. Carcinogenicity in animal models, in the patient population, or both, as reported by the Interna- cal effect) or cause irreversible effects. As the tional Agency for Research on Cancer (IARC) use and number of these potent drugs increase, 3. Teratogenicity or fertility impairment in animal so do opportunities for hazardous exposures studies or in treated patients among health care workers. For example, an- 4. Evidence of serious organ or other toxicity at low doses in animal models or treated patients. †All drugs have toxic side effects, but some exhibit tox- icity at low doses. The level of toxicity reflects a con- al. 2002]. OELs in this range are typically established tinuum from relatively nontoxic to production of toxic for potent or toxic drugs in the pharmaceutical indus- effects in patients at low doses (for example, a few mil- try. Under all circumstances, an evaluation of all avail- ligrams or less). For example, a daily therapeutic dose able data should be conducted to protect health care of 10 mg/day or a dose of 1 mg/kg per day in labora- workers. tory animals that produces serious organ toxicity, de- ‡In evaluating mutagenicity for potentially hazardous velopmental toxicity, or reproductive toxicity has been drugs, responses from multiple test systems are needed used by the pharmaceutical industry to develop occu- before precautions can be required for handling such pational exposure limits (OELs) of less than 10 µg/m3 agents. The EPA evaluations include the type of cells af- after applying appropriate uncertainty factors [Sargent fected and in vitro versus in vivo testing [51 Fed. Reg. and Kirk 1988; Naumann and Sargent 1997; Sargent et 34006–34012 (1986)]. 2 tineoplastic drugs such as cyclophosphamide How to Generate You Own List of have immunosuppressant effects that proved Hazardous Drugs beneficial for treating nonmalignant diseas- es such as rheumatoid arthritis and multiple sclerosis [Baker et al. 1987; Moody et al. 1987; The OSHA hazard communication standard Chabner et al. 1996; Abel 2000]. [29 CFR 1910.1200] requires employers to de- velop a hazard communication program appro- This document presents criteria and sources of priate for their unique workplace. An essential information for determining whether a drug is part of the program is the identification of all hazardous. When a drug has been judged to be hazardous drugs a worker may encounter hazardous, the various precautions outlined in in the facility. Compliance with the OSHA the Alert should be applied when handling that hazard communication standard entails (1) drug. Also included is a list of drugs that should evaluating whether these drugs meet one or be handled as hazardous. This list is based on more of the criteria for defining hazardous a compilation of lists from four health care fa- drugs and (2) posting a list of the hazardous cilities, one drug manufacturers’ organization, drugs to ensure worker safety. Institutions may and NIOSH. wish to compare their lists to the sample listing in this document or on the NIOSH Web site. In addition to using the list of hazardous drugs presented here, each organization should cre- It is not likely that every health care provider ate its own list of drugs considered to be haz- or facility will use all drugs that have received ardous. This document presents guidance for U.S. Food and Drug Administration (FDA) ap- making such a facility-specific list (see section proval, and the OSHA hazard communication entitled How to Generate your own List of Haz- standard does not mandate evaluation of every ardous Drugs). Once this list is made, newly marketed drug.
Recommended publications
  • Treatment of Localized Extranodal NK/T Cell Lymphoma, Nasal Type: a Systematic Review Seok Jin Kim†, Sang Eun Yoon† and Won Seog Kim*
    Kim et al. Journal of Hematology & Oncology (2018) 11:140 https://doi.org/10.1186/s13045-018-0687-0 REVIEW Open Access Treatment of localized extranodal NK/T cell lymphoma, nasal type: a systematic review Seok Jin Kim†, Sang Eun Yoon† and Won Seog Kim* Abstract Extranodal natural killer/T cell lymphoma (ENKTL), nasal type, presents predominantly as a localized disease involving the nasal cavity and adjacent sites, and the treatment of localized nasal ENKTL is a major issue. However, given its rarity, there is no standard therapy based on randomized controlled trials and therefore a lack of consensus on the treatment of localized nasal ENKTL. Currently recommended treatments are based mainly on the results of phase II studies and retrospective analyses. Because the previous outcomes of anthracycline-containing chemotherapy were poor, non- anthracycline-based chemotherapy regimens, including etoposide and L-asparaginase, have been used mainly for patients with localized nasal ENKTL. Radiotherapy also has been used as a main component of treatment because it can produce a rapid response. Accordingly, the combined approach of non-anthracycline-based chemotherapy with radiotherapy is currently recommended as a first-line treatment for localized nasal ENKTL. This review summarizes the different approaches for the use of non-anthracycline-based chemotherapy with radiotherapy including concurrent, sequential, and sandwich chemoradiotherapy, which have been proposed as a first-line treatment for newly diagnosed patients with localized nasal ENKTL. Keywords: Extranodal NK/T cell lymphoma, Chemoradiotherapy, Localized disease Background Treatment for newly diagnosed patients with localized Extranodal natural killer/T cell lymphoma (ENKTL), nasal nasal ENKTL type, is a rare subtype of non-Hodgkin lymphoma [1].
    [Show full text]
  • A Pilot Trial of Clofarabine Added to Standard Busulfan and Fludarabine for Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation
    NCT# 01596699 A Pilot Trial of Clofarabine Added to Standard Busulfan and Fludarabine for Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation Protocol Number: CC #110819 Version Number: 7.0 Version Date: June 6, 2013 Study Drug: Clofarabine Principal Investigator (Sponsor-Investigator) Christopher C. Dvorak, MD Co-Investigators Janel Long-Boyle, PharmD, PhD Morton Cowan, MD Biljana Horn, MD James Huang, MD Robert Goldsby, MD Kristin Ammon, MD Justin Wahlstrom, MD Statistician Stephen Shiboski, PhD Clinical Research Coordinator Revision History Version #1.0 9/19/11 Version #2.0 11/8/11 Version #3.1 02/23/12 Version #4.0 04/10/12 Version #5.0 04/30/12 Version #6.0 08/09/12 Version #7.0 06/07/13 Clofarabine Version 4.0, 04/10/12 Page 1 of 33 1.0 Hypothesis and Specific Aims: 1.1 Hypothesis: The addition of Clofarabine to standard Busulfan and Fludarabine prior to allogeneic hematopoietic cell transplant (HCT) will be safe and will improve engraftment rates of children with non-malignant diseases or decrease relapse rates of patients with high-risk myeloid malignancies. 1.2 Specific Aims: 1.2.1 Primary Objective: To determine the toxicity of the addition of Clofarabine to a conditioning backbone of Busulfan plus Fludarabine in patients with myeloid malignancies and non-malignant diseases undergoing allogeneic HCT. 1.2.2 Secondary Objectives: a. To determine if the addition of Clofarabine to a conditioning backbone of Busulfan plus Fludarabine improves the engraftment rate of patients with non-malignant diseases (Stratum A) undergoing allogeneic HCT as compared to historic controls.
    [Show full text]
  • Highlights of Prescribing Information
    HIGHLIGHTS OF PRESCRIBING INFORMATION --------------------------WARNINGS AND PRECAUTIONS--------------------­ These highlights do not include all the information needed to use • New onset or worsening renal impairment: Can include acute VIREAD safely and effectively. See full prescribing information renal failure and Fanconi syndrome. Assess creatinine clearance for VIREAD. (CrCl) before initiating treatment with VIREAD. Monitor CrCl and ® serum phosphorus in patients at risk. Avoid administering VIREAD (tenofovir disoproxil fumarate) tablets, for oral use VIREAD with concurrent or recent use of nephrotoxic drugs. (5.3) VIREAD® (tenofovir disoproxil fumarate) powder, for oral use • Coadministration with Other Products: Do not use with other Initial U.S. Approval: 2001 tenofovir-containing products (e.g., ATRIPLA, COMPLERA, and TRUVADA). Do not administer in combination with HEPSERA. WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH (5.4) STEATOSIS and POST TREATMENT EXACERBATION OF HEPATITIS • HIV testing: HIV antibody testing should be offered to all HBV- infected patients before initiating therapy with VIREAD. VIREAD See full prescribing information for complete boxed warning. should only be used as part of an appropriate antiretroviral • Lactic acidosis and severe hepatomegaly with steatosis, combination regimen in HIV-infected patients with or without HBV including fatal cases, have been reported with the use of coinfection. (5.5) nucleoside analogs, including VIREAD. (5.1) • Decreases in bone mineral density (BMD): Consider assessment • Severe acute exacerbations of hepatitis have been reported of BMD in patients with a history of pathologic fracture or other in HBV-infected patients who have discontinued anti- risk factors for osteoporosis or bone loss. (5.6) hepatitis B therapy, including VIREAD. Hepatic function • Redistribution/accumulation of body fat: Observed in HIV-infected should be monitored closely in these patients.
    [Show full text]
  • 214120Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 214120Orig1s000 MULTI-DISCIPLINE REVIEW Summary Review Office Director Cross Discipline Team Leader Review Clinical Review Non-Clinical Review Statistical Review Clinical Pharmacology Review NDA Multidisciplinary Review and Evaluation Application Number NDA 214120 Application Type Type 3 Priority or Standard Priority Submit Date 3/3/2020 Received Date 3/3/2020 PDUFA Goal Date 9/3/2020 Office/Division OOD/DHM1 Review Completion Date 9/1/2020 Applicant Celgene Corporation Established Name Azacitidine (Proposed) Trade Name Onureg Pharmacologic Class Nucleoside metabolic inhibitor Formulations Tablet (200 mg, 300 mg) (b) (4) Applicant Proposed Indication/Population Recommendation on Regulatory Regular approval Action Recommended Indication/ For continued treatment of adult patients with acute Population myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy. SNOMED CT for the Recommended 91861009 Indication/Population Recommended Dosing Regimen 300 mg orally daily on Days 1 through 14 of each 28-day cycle Reference ID: 4664570 NDA Multidisciplinary Review and Evaluation NDA 214120 Onureg (azacitidine tablets) TABLE OF CONTENTS TABLE OF CONTENTS ................................................................................................................................... 2 TABLE OF TABLES .......................................................................................................................................
    [Show full text]
  • A Phase II Study of Paclitaxel and Capecitabine As a First-Line Combination Chemotherapy for Advanced Gastric Cancer
    British Journal of Cancer (2008) 98, 316 – 322 & 2008 Cancer Research UK All rights reserved 0007 – 0920/08 $30.00 www.bjcancer.com A phase II study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer Clinical Studies HJ Kang1, HM Chang1, TW Kim1, M-H Ryu1, H-J Sohn1, JH Yook2,STOh2, BS Kim2, J-S Lee1 and Y-K Kang*,1 1 2 Division of Oncology, Department of Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea; Department of Surgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea Paclitaxel and capecitabine, which have distinct mechanisms of action and toxicity profiles, have each shown high activity as single agents in gastric cancer. Synergistic interaction between these two drugs was suggested by taxane-induced upregulation of thymidine phosphorylase. We, therefore, evaluated the antitumour activity and toxicities of paclitaxel and capecitabine as first-line therapy in patients with advanced gastric cancer (AGC). Patients with histologically confirmed unresectable or metastatic AGC were treated À2 À2 with capecitabine 825 mg m p.o. twice daily on days 1–14 and paclitaxel 175 mg m i.v. on day 1 every 3 weeks until disease progression or unacceptable toxicities. Between June 2002 and May 2004, 45 patients, of median age 57 years (range ¼ 38–73 years), were treated with the combination of capecitabine and paclitaxel. After a median 6 cycles (range ¼ 1–9 cycles) of chemotherapy, 43 were evaluable for toxicity and response. A total of 2 patients showed complete response and 20 showed partial response making the overall response rate 48.9% (95% CI ¼ 30.3–63.5%).
    [Show full text]
  • CASODEX (Bicalutamide)
    HIGHLIGHTS OF PRESCRIBING INFORMATION • Gynecomastia and breast pain have been reported during treatment with These highlights do not include all the information needed to use CASODEX 150 mg when used as a single agent. (5.3) CASODEX® safely and effectively. See full prescribing information for • CASODEX is used in combination with an LHRH agonist. LHRH CASODEX. agonists have been shown to cause a reduction in glucose tolerance in CASODEX® (bicalutamide) tablet, for oral use males. Consideration should be given to monitoring blood glucose in Initial U.S. Approval: 1995 patients receiving CASODEX in combination with LHRH agonists. (5.4) -------------------------- RECENT MAJOR CHANGES -------------------------- • Monitoring Prostate Specific Antigen (PSA) is recommended. Evaluate Warnings and Precautions (5.2) 10/2017 for clinical progression if PSA increases. (5.5) --------------------------- INDICATIONS AND USAGE -------------------------- ------------------------------ ADVERSE REACTIONS ----------------------------- • CASODEX 50 mg is an androgen receptor inhibitor indicated for use in Adverse reactions that occurred in more than 10% of patients receiving combination therapy with a luteinizing hormone-releasing hormone CASODEX plus an LHRH-A were: hot flashes, pain (including general, back, (LHRH) analog for the treatment of Stage D2 metastatic carcinoma of pelvic and abdominal), asthenia, constipation, infection, nausea, peripheral the prostate. (1) edema, dyspnea, diarrhea, hematuria, nocturia, and anemia. (6.1) • CASODEX 150 mg daily is not approved for use alone or with other treatments. (1) To report SUSPECTED ADVERSE REACTIONS, contact AstraZeneca Pharmaceuticals LP at 1-800-236-9933 or FDA at 1-800-FDA-1088 or ---------------------- DOSAGE AND ADMINISTRATION ---------------------- www.fda.gov/medwatch The recommended dose for CASODEX therapy in combination with an LHRH analog is one 50 mg tablet once daily (morning or evening).
    [Show full text]
  • A Phase II Study of Capecitabine and Docetaxel Combination Chemotherapy in Patients with Advanced Gastric Cancer
    British Journal of Cancer (2004) 90, 1329 – 1333 & 2004 Cancer Research UK All rights reserved 0007 – 0920/04 $25.00 www.bjcancer.com A phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer YH Park*,1, B-Y Ryoo1, S-J Choi1and H-T Kim1 1 Division of Haematology and Oncology, Department of Internal Medicine, Korea Institute of Radiological and Medical Science, Seoul, Korea Clinical Capecitabine and docetaxel have considerable single-agent activity in gastric cancer with distinct mechanisms of action and no overlap of key toxicities. A synergistic interaction between these two drugs is mediated by taxane-induced upregulation of thymidine phosphorylase. We investigated the activity and the feasibility of capecitabine and docetaxel combination chemotherapy in patients with previously untreated advanced gastric cancer (AGC). From September 2001 to March 2003, 42 patients with AGC received À2 À2 21-day cycles of oral capecitabine (1250 mg m twice daily on days 1–14) and docetaxel (75 mg m i.v. on day 1). The patients received a total of 164 cycles of chemotherapy. The median age was 53.5 years (range 33–73 years). The overall response rate in the 38 efficacy-evaluable patients was 60% (95% confidence interval, 45–74%). The median progression-free survival was 5.2 months (range, 1.0–15.5 þ months) and the median overall survival was 10.5 months (range, 2.9–23.7 þ months). The most common grade 3/4 adverse events were hand–foot syndrome (HFS: G3 50%), neutropenia (15%) and leucopenia (12%). Further studies of this combination are clearly warranted, albeit with lower doses of both agents (1000 mg mÀ2 twice daily and 60 mg mÀ2) to reduce the rate of HFS and onycholysis.
    [Show full text]
  • COVID-19—The Potential Beneficial Therapeutic Effects of Spironolactone During SARS-Cov-2 Infection
    pharmaceuticals Review COVID-19—The Potential Beneficial Therapeutic Effects of Spironolactone during SARS-CoV-2 Infection Katarzyna Kotfis 1,* , Kacper Lechowicz 1 , Sylwester Drozd˙ zal˙ 2 , Paulina Nied´zwiedzka-Rystwej 3 , Tomasz K. Wojdacz 4, Ewelina Grywalska 5 , Jowita Biernawska 6, Magda Wi´sniewska 7 and Miłosz Parczewski 8 1 Department of Anesthesiology, Intensive Therapy and Acute Intoxications, Pomeranian Medical University in Szczecin, 70-111 Szczecin, Poland; [email protected] 2 Department of Pharmacokinetics and Monitored Therapy, Pomeranian Medical University, 70-111 Szczecin, Poland; [email protected] 3 Institute of Biology, University of Szczecin, 71-412 Szczecin, Poland; [email protected] 4 Independent Clinical Epigenetics Laboratory, Pomeranian Medical University, 71-252 Szczecin, Poland; [email protected] 5 Department of Clinical Immunology and Immunotherapy, Medical University of Lublin, 20-093 Lublin, Poland; [email protected] 6 Department of Anesthesiology and Intensive Therapy, Pomeranian Medical University in Szczecin, 71-252 Szczecin, Poland; [email protected] 7 Clinical Department of Nephrology, Transplantology and Internal Medicine, Pomeranian Medical University, 70-111 Szczecin, Poland; [email protected] 8 Department of Infectious, Tropical Diseases and Immune Deficiency, Pomeranian Medical University in Szczecin, 71-455 Szczecin, Poland; [email protected] * Correspondence: katarzyna.kotfi[email protected]; Tel.: +48-91-466-11-44 Abstract: In March 2020, coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 was declared Citation: Kotfis, K.; Lechowicz, K.; a global pandemic by the World Health Organization (WHO). The clinical course of the disease is Drozd˙ zal,˙ S.; Nied´zwiedzka-Rystwej, unpredictable but may lead to severe acute respiratory infection (SARI) and pneumonia leading to P.; Wojdacz, T.K.; Grywalska, E.; acute respiratory distress syndrome (ARDS).
    [Show full text]
  • Ciera L. Patzke, Alison P. Duffy, Vu H. Duong, Firas El Chaer 4, James A
    Journal of Clinical Medicine Article Comparison of High-Dose Cytarabine, Mitoxantrone, and Pegaspargase (HAM-pegA) to High-Dose Cytarabine, Mitoxantrone, Cladribine, and Filgrastim (CLAG-M) as First-Line Salvage Cytotoxic Chemotherapy for Relapsed/Refractory Acute Myeloid Leukemia Ciera L. Patzke 1, Alison P. Duffy 1,2, Vu H. Duong 1,3, Firas El Chaer 4, James A. Trovato 2, Maria R. Baer 1,3, Søren M. Bentzen 1,3 and Ashkan Emadi 1,3,* 1 Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, MD 21201, USA; [email protected] (C.L.P.); aduff[email protected] (A.P.D.); [email protected] (V.H.D.); [email protected] (M.R.B.); [email protected] (S.M.B.) 2 School of Pharmacy, University of Maryland, Baltimore, MD 21201, USA; [email protected] 3 School of Medicine, University of Maryland, Baltimore, MD 21201, USA 4 School of Medicine, University of Virginia, Charlottesville, VA 22908, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-410-328-2596 Received: 10 January 2020; Accepted: 13 February 2020; Published: 16 February 2020 Abstract: Currently, no standard of care exists for the treatment of relapsed or refractory acute myeloid leukemia (AML). We present our institutional experience with using either CLAG-M or HAM-pegA, a novel regimen that includes pegaspargase. This is a retrospective comparison of 34 patients receiving CLAG-M and 10 receiving HAM-pegA as first salvage cytotoxic chemotherapy in the relapsed or refractory setting. Composite complete response rates were 47.1% for CLAG-M and 90% for HAM-pegA (p = 0.027).
    [Show full text]
  • Novel Therapeutics for Epstein–Barr Virus
    molecules Review Novel Therapeutics for Epstein–Barr Virus Graciela Andrei *, Erika Trompet and Robert Snoeck Laboratory of Virology and Chemotherapy, Department of Microbiology and Immunology, Rega Institute for Medical Research, KU Leuven, 3000 Leuven, Belgium; [email protected] (E.T.); [email protected] (R.S.) * Correspondence: [email protected]; Tel.: +32-16-321-915 Academic Editor: Stefano Aquaro Received: 15 February 2019; Accepted: 4 March 2019; Published: 12 March 2019 Abstract: Epstein–Barr virus (EBV) is a human γ-herpesvirus that infects up to 95% of the adult population. Primary EBV infection usually occurs during childhood and is generally asymptomatic, though the virus can cause infectious mononucleosis in 35–50% of the cases when infection occurs later in life. EBV infects mainly B-cells and epithelial cells, establishing latency in resting memory B-cells and possibly also in epithelial cells. EBV is recognized as an oncogenic virus but in immunocompetent hosts, EBV reactivation is controlled by the immune response preventing transformation in vivo. Under immunosuppression, regardless of the cause, the immune system can lose control of EBV replication, which may result in the appearance of neoplasms. The primary malignancies related to EBV are B-cell lymphomas and nasopharyngeal carcinoma, which reflects the primary cell targets of viral infection in vivo. Although a number of antivirals were proven to inhibit EBV replication in vitro, they had limited success in the clinic and to date no antiviral drug has been approved for the treatment of EBV infections. We review here the antiviral drugs that have been evaluated in the clinic to treat EBV infections and discuss novel molecules with anti-EBV activity under investigation as well as new strategies to treat EBV-related diseases.
    [Show full text]
  • Promising Findings for SCC in Organ Transplant Recipients Repeated PDT Treatments May Reduce the Incidence of Sccs in This High-Risk Population
    Oncology Watch Cyclic Photodynamic Therapy: Promising Findings for SCC in Organ Transplant Recipients Repeated PDT treatments may reduce the incidence of SCCs in this high-risk population. By Jonathan Wolfe, MD hotodynamic therapy with 5-aminolevulinic acid SOTRs typically undergo chemoprophylaxis with sys- (ALA, Levulan, DUSA Pharmaceuticals) has temic retinoids, although there have been few ran- become established as a safe and effective option domized controlled trials to quantify their benefit. Pfor the management of AKs (see the January edi- Acitretin is probably the most frequently used agent,3 tion, available at PracticalDermatology.com). The drug but isotretinoin and etretinate are also used, and there is indicated, along with blue light application, for the is anecdotal evidence to support the use of treatment of minimally to moderately thick actinic bexarotene.4 Of note, rebound flares have been associ- keratoses of the face or scalp. However, there has ated with discontinuation of retinoids, leading some to been increasing interest in the role of PDT to manage advocate chemoprevention as a lifelong therapy.3 other types of skin cancers. A recent study shows that the procedure may be effective for reducing the inci- An Emerging Option dence of squamous cell carcinoma (SCC) in solid Given the concerns about high rates of NMSCs in organ transplant recipients (SOTR). transplant recipients, there is interest in identifying optimal treatment and prevention strategies. While Skin Cancer and SOTRs retinoid chemoprophylaxis is an important and effec- Compared to the general population, solid organ trans- tive option, additional interventions are welcome. plant recipients are at higher risk of skin cancer, with Recent findings suggest a role for cyclic 5-ALA PDT up to a 100-fold estimated increase in the relative risk therapy.5 Twelve high-risk SOTRs received cyclic PDT of squamous cell carcinoma (SCC) compared to the treatments at four- to eight-week intervals for two non-transplanted population.
    [Show full text]
  • Incidence of Differentiation Syndrome Associated with Treatment
    Journal of Clinical Medicine Review Incidence of Differentiation Syndrome Associated with Treatment Regimens in Acute Myeloid Leukemia: A Systematic Review of the Literature Lucia Gasparovic 1, Stefan Weiler 1,2, Lukas Higi 1 and Andrea M. Burden 1,* 1 Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, 8093 Zurich, Switzerland; [email protected] (L.G.); [email protected] (S.W.); [email protected] (L.H.) 2 National Poisons Information Centre, Tox Info Suisse, Associated Institute of the University of Zurich, 8032 Zurich, Switzerland * Correspondence: [email protected]; Tel.: +41-76-685-22-56 Received: 30 August 2020; Accepted: 14 October 2020; Published: 18 October 2020 Abstract: Differentiation syndrome (DS) is a potentially fatal adverse drug reaction caused by the so-called differentiating agents such as all-trans retinoic acid (ATRA) and arsenic trioxide (ATO), used for remission induction in the treatment of the M3 subtype of acute myeloid leukemia (AML), acute promyelocytic leukemia (APL). However, recent DS reports in trials of isocitrate dehydrogenase (IDH)-inhibitor drugs in patients with IDH-mutated AML have raised concerns. Given the limited knowledge of the incidence of DS with differentiating agents, we conducted a systematic literature review of clinical trials with reports of DS to provide a comprehensive overview of the medications associated with DS. In particular, we focused on the incidence of DS reported among the IDH-inhibitors, compared to existing ATRA and ATO therapies. We identified 44 published articles, encompassing 39 clinical trials, including 6949 patients. Overall, the cumulative incidence of DS across all treatment regimens was 17.7%.
    [Show full text]